Clinical Trial Update: Effect of Insulin Sensitizer Metformin on AD Biomarkers [Phase 2]

View source ↗

Summary

Phase 2 trial assessing metformin, an insulin sensitizer, on Alzheimer's disease biomarkers; completed with results posted in 2017.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Alzheimer Disease
• Dementia
• Vascular Dementia

Drugs mentioned

• metformin (metformin)

Snippet

Sponsor: University of Pennsylvania | Conditions: Alzheimer's Disease, Vascular Dementia | Phase 2 | Status: COMPLETED | Results posted: 2017-09-21